Redhill Biopharma Ltd ADR Dossier
Qualitative Analysis
Business overview
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical-stage, proprietary, orally-administered small molecule drugs for gastrointestinal (GI) diseases, infectious diseases, and oncology. The company's commercial portfolio is anchored by Talicia®, an FDA-approved treatment to eradicate Helicobacter pylori (H. pylori) infection in adults. In late 2025, RedHill transitioned its direct Talicia commercial operations to Talicia Holdings Inc. (THI), a joint venture owned 70% by RedHill and 30% by Cumberland Pharmaceuticals Inc., which now co-commercializes the drug in the U.S.. RedHill's late-stage clinical pipeline includes opaganib (targeting oncology, viral, and radiation indications), RHB-102 (Bekinda®) for GLP-1/GIP-associated GI intolerance and gastroenteritis, RHB-204 for Crohn's disease, and RHB-107 (upamostat) for pandemic preparedness and oncology.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Restructuring commercial operations by transferring direct U.S. Talicia commercialization to Talicia Holdings Inc. (THI), a joint venture owned 70% by RedHill and 30% by Cumberland Pharmaceuticals. This shifts RedHill away from high direct commercialization costs while retaining a 70% economic interest in the joint venture.
Expected impact: Accelerates Talicia sales growth by leveraging Cumberland's national sales force and marketing support, while delivering significant operational efficiencies.
Out-licensing the exclusive worldwide development and commercialization rights for RHB-102 (Bekinda), excluding North America (U.S., Canada, and Mexico), to Hyloris Pharmaceuticals.
Expected impact: Provides RedHill with non-dilutive funding through an upfront payment, up to $60 million in potential milestone payments, and tiered royalties up to mid-20s percent on net sales.
Securing a flexible financing facility through an Any Market Purchase Agreement with Alumni Capital LP, allowing RedHill to sell up to $10 million of American Depositary Shares (ADSs) to Alumni.
Expected impact: Provides the company with flexible equity financing capacity to support working capital and pipeline development as needed.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Transforms the commercialization model for RedHill's flagship product, Talicia, by leveraging Cumberland's established U.S. commercial footprint and national sales force.
Terms: Cumberland invested $4 million for a 30% equity interest in Talicia Holdings Inc. (THI), payable in two equal tranches of $2 million. Net revenues from U.S. Talicia sales are shared equally (50/50) between Cumberland and THI, with RedHill holding a 70% interest in THI.
Expands the global reach of RHB-102 (Bekinda) outside of North America, utilizing Hyloris's regulatory and commercial expertise.
Terms: Includes an upfront payment, up to $60 million in potential milestone payments contingent on commercial targets, and tiered royalties up to mid-20s percent on net sales.